Introduction {#sec1-1}
============

The population is aging and concomitantly patients present an increasing number of comorbidities.\[[@ref1]\] For this frail population, the risk related to the surgical procedure might outweigh the benefit of the surgical intervention.\[[@ref2]\] This restriction applies in particular for aortic valve replacement.\[[@ref3]\] However, transcatheter aortic valve implantation (TAVI) has been proposed as a valid alternative to surgical aortic valve replacement for patients with severe aortic valve stenosis deemed to be at high surgical risk\[[@ref4]\] and more recently, at intermediate surgical risk.\[[@ref5][@ref6]\] Although many trials have shown the efficacy of a TAVI over a surgical replacement for these patients, no agreement on the most suitable type of anesthesia has been advocated yet.\[[@ref4]\] Sedation for TAVI presents several advantages such as fewer episodes of significant hypotension, lower intraoperative vasoconstrictor use, faster turnover, central nervous system assessment to determine the occurrences of strokes, and finally, more rapid postoperative recovery.\[[@ref4][@ref7]\] In contrast, general anesthesia (GA) has been advocated to be associated with significantly less paravalvular leaks (PVLs) compared to sedation.\[[@ref8]\] Such difference is probably related to the insertion of a transesophageal echocardiography probe (TEE) during GA that guides the correct valve deployment and detects PVL requiring postimplantation dilation.\[[@ref9]\] The presence of PVL is of paramount importance because it has been stated that PVL is associated with increased short- and long-term mortality post-TAVI.\[[@ref10]\] It should be underlined that PVL grading post-TAVI lacks harmonization across institutions\[[@ref11]\] although standardized end point definitions for TAVI have been suggested in that respect through the Valve Academic Research Consortium.\[[@ref12]\] To the best of our knowledge, only one recent study investigated the impact of PVL severity after TAVI on long-term mortality as the primary outcome using the Valve Academic Research Consortium (VARC)-2 criteria.\[[@ref13]\] This trial showed that increased long-term mortality was observed only in patients with moderate-to-severe PVL.\[[@ref14]\] In an effort to determine whether conscious sedation for TAVI without TEE guidance could be performed deprived of increased incidence of postimplantation PVL that could have an impact on long-term mortality, we conducted the present study. The objective of the current observational investigation was to compare the incidence of PVL using the VARC-2 criteria between patients receiving GA (TAVI-GA) with TEE guidance during the procedure and patients receiving local anesthesia infiltration plus sedation without TEE guidance (TAVI-S). We hypothesized that, in an experienced center, defined as a center that have performed more than 200 TAVI procedures for 3 consecutive years, TAVI-GA with TEE guidance is not associated with a lower incidence of moderate-to-severe PVL compared to TAVI-S alone.

Methods {#sec1-2}
=======

Patients {#sec2-1}
--------

This single-center retrospective observational trial conducted in the Department of Cardiac Anesthesia and Coronary Care Unit is an ancillary study. Data were collected prospectively for the French Aortic National CoreValve and Edwards 2 France TAVI registry, for which the Ethics Review Board allowed a waiver of the written informed consent because the investigation is under the provisions governing biomedical and routine care research. After approval for the present ancillary study from our institutional ethics committee (Comité de Protection des Personnes Sud-Ouest et Outre Mer III, Bordeaux, France/agreement number DC 2016/101) and agreement from the Commission Nationale de l\'Informatique et des Libertés (registration number 912,449), we analyzed data from all patients with severe aortic stenosis scheduled to undergo a TAVI in Bordeaux University Hospital from January 2013 to December 2014. Patients included in the study were 18 years old or over were scheduled to undergo a valve change by transcatheter implantation and gave explicit consent for this procedure. We excluded patients undergoing a GA without TEE guidance and patients undergoing a TAVI under sedation with the insertion of a TEE.

Perioperative management-anesthesia and procedure {#sec2-2}
-------------------------------------------------

A detailed transthoracic echocardiography (TTE) and a multisliced computed tomography with iodine contrast media injection were performed in all patients before the procedure. Then, a heart team constituted of interventional cardiologists, cardiac surgeons, and cardiac anesthesiologists determined the valve type to implant, the access route, and the type of anesthesia depending on patients' characteristics. Most cases were performed percutaneously through a transfemoral approach. The heart team opted for the transcarotid implantation when the femoral approach was impeded by the anatomy or the atherosclerotic vascular disease severity affecting the lower limbs. All procedures took place in a hybrid room. One hour before the intervention, anesthesiologists prescribed 0.1 mg/kg of oral midazolam. Before the procedure, cardiologists prescribed aspirin and clopidogrel. This combination of antithrombotic drugs was continued for 6 months after the implantation if no contraindication was found. Upon arrival in the hybrid operating room, patients were transferred to the operating table. Then, they were monitored with a 2-channel electrocardiogram, an arterial line, a pulse oximeter, and a bispectral index (BIS). Two IV lines were inserted in all patients. One was devoted for anesthetic drugs infusion only, while the other large bore one was dedicated to other drugs' administration and rapid fluid administration. The TAVI-S group received a facial mask for O~2~ delivery. This group also received an injection of 30--40 cc of lidocaine 1% at the site of procedural sheaths insertion and propofol administration using a target-controlled infusion technique for conscious sedation with spontaneous breathing with BIS values maintained around 65. In contrast, the TAVI-GA received a total intravenous anesthesia-technique using target-controlled infusion models for both remifentanil and propofol. Cisatracurium 0.15 mg/kg was administered to facilitate endotracheal intubation. After the intubation, lungs were ventilated at normocapnia with a 50% FiO~2~. After induction, anesthetics drugs' infusion rates were changed if necessary to maintain BIS values within 40 and 60. A TEE probe was inserted immediately after intubation and connected to an ultrasound machine (Vivid9, GE Healthcare device, Chalfont St 154 Giles, UK). The bioprostheses implanted were either the self-expandable CoreValve valve (Medtronic, Minneapolis, MN, USA) or the balloon-expandable Edwards Sapien XT heart valve system (Edwards Lifesciences, Irvine, CA). The procedure was performed by same set of physician. The details of the TAVI procedure have been thoroughly described previously.\[[@ref3]\] Valves were deployed under fluoroscopic guidance in the TAVI-S group and by fluoroscopy and TEE in the TAVI-GA group. In the TAVR-S group, PVL was graded through hemodynamic\[[@ref15]\] and fluoroscopic measures.\[[@ref11]\] In the TAVR-GA group, PVL was graded also using intraoperative TEE measurements accomplished by a certified echocardiographer (S. L.). A postdilation was performed when PVL wasere deemed moderate or severe.

Details concerning the echocardiographic assessment {#sec2-3}
---------------------------------------------------

TTE was systematically performed and analyzed by the same set of experts in echocardiography before TAVI, in coronary care unit right after the procedure, at 5 days and finally, at 30 days after the implantation. After the valve implantation, only TTE was used to assess PVL, which were graded using the VARC-2 criteria described in [Table 1](#T1){ref-type="table"}.\[[@ref12]\] Patients were categorized into two groups according to the grade of PVL: none to mild and moderate to severe. Left ventricular ejection fraction was measured using the Simpson biplane methods. Mitral regurgitation was also assessed at baseline, at 5 days, and at 30 days after the implantation according to the recommendations of the American Society of Echocardiography.\[[@ref16]\]

###### 

Valve Academic Research Consortium-2 criteria for prosthetic aortic valve regurgitation

  Classification of the regurgitation severity                               Mild                              Moderate       Severe
  -------------------------------------------------------------------------- --------------------------------- -------------- --------------------------
  Semi-quantitative parameters                                                                                                
  Diastolic flow reversal in the descending aorta with pulsed wave Doppler   Absent or brief early diastolic   Intermediate   Prominent, holodiastolic
  Circumferential extent of prosthetic valve PVL (%)                         \<10                              10-29          ≥30%
  Quantitative parameters                                                                                                     
  Regurgitant volume (mL/beat)                                               \< 30                             30-59          ≥60
  Regurgitant fraction (%)                                                   \<30                              30-49          ≥50%
  EROA (cm^2^)                                                               0.10                              0.10-0.29      ≥0.30

EROA: Effective regurgitant orifice area

Data collection and statistical analysis {#sec2-4}
----------------------------------------

Demographic, clinical, and echocardiographic patients' characteristics, procedural findings, postprocedure echocardiographic patients' characteristics, intra- and postprocedure complication related, as well as, endpoints data were prospectively collected for the France TAVI database and analyzed for the present ancillary trial. Clinical follow-up was carried out at 30 days in clinical visits and then through telephone contact at 12 months after the valve implantation. The primary outcome of the study was the incidence of moderate-to-severe PVL at 30 days after the procedure. The secondary outcomes were the incidence of moderate-to-severe PVL immediately after the procedure, and at 5 days, the all-cause mortality in-hospital, at 30 days and at 1 year after the procedure, as well as, the incidence of procedure-related complications such as conversion to open surgery, coronary obstruction, new permanent pacemaker, postprocedural myocardial infarction, tamponade, major stroke, major vascular access-site bleeding, life-threatening bleeding, postimplantation infection, acute kidney injury Stage 3, renal replacement therapy rate, and finally, the length of hospital stay. Patients lost to follow-up were not included in the analysis. Determination of the sample size was calculated to show a difference between the incidences of PVL having an impact on the long-term survival in an experienced center, and the one reported nationwide. According to the French registry, the national incidence of moderate-to-severe PVL that could have an impact on long-term survival is 17.1% at 30 days after the implantation.\[[@ref17]\] The aim of our investigation was to detect a 75% proportion difference on the incidence of PVL between an experienced center and the incidence of moderate-to-severe PVL at 30 days after the implantation of the French TAVI registry. An alpha error of 0.05 and a power of 0.8 were chosen, resulting in a sample size of 50 patients for each group. Considering a potential loss to follow-up into account, at least sixty patients per group were planned. Data collected were analyzed using the Statistical Package for the Social Sciences (IBM, SPSS Statistics 20, Chicago, IL, USA). Results are presented as mean with standard deviation for continuous variables and as number and percentage (%) for categorical data. Comparisons of continuous variables were performed using the Student\'s *t*-test. Comparisons for categorical data were performed using the Fisher\'s exact test. *P* = 0.05 was considered statistically significant. To reduce the impact of anesthesia procedure-selection bias on study outcomes, a propensity score approach was performed for the procedural findings and the postprocedural findings of interest using a logistic statistical model including the baseline covariates found to be significantly different between the two groups. Study end points of interest where then analyzed using an ANCOVA (for continuous endpoints) or a regression (for categorical endpoints) model adjusting for propensity score as a continuous covariate.

Results {#sec1-3}
=======

From the January 1, 2013, to December 31, 2014, 268 patients were scheduled to undergo a TAVI in Bordeaux University Hospital. Fifteen patients were excluded from the analysis in the TAVI-GA group because no TEE probe was inserted. Two patients were excluded in the TAVI-S group because they had a TEE probe inserted during the procedure to rule out the presence of a cardiac tamponade. Finally, 234 patients were included for final analysis. Of those, 168 were implanted under sedation and 66 under GA. The flowchart of the investigation is depicted in [Figure 1](#F1){ref-type="fig"}. Twenty-two patients did not show up for the clinical visit at 30 days, and 12 patients were lost to follow-up at 1 year. Patients' preoperative characteristics are presented in [Table 2](#T2){ref-type="table"}. Both groups were similar, except for histories of diabetes mellitus, peripheral vascular disease, previous mitral valve surgery, and concomitant significant coronary artery disease, which were more frequent in the TAVI-GA group. Procedural findings are shown in [Table 3](#T3){ref-type="table"}. No significant differences were found between the two groups except for the duration of fluoroscopy, and the absolute quantity of contrast-medium injected. However, when the latter was indexed to the body surface area, both groups were similar.

![Flowchart of the trial](ACA-21-277-g001){#F1}

###### 

Pre-implantation patients' characteristics

  Patients' characteristics                                 Total (*n*=234)   TAVI-GA (*n*=66)   TAVI-S (*n*=168)   *P*
  --------------------------------------------------------- ----------------- ------------------ ------------------ ---------
  Clinical characteristics                                                                                          
   Age (years)                                              81.3±8.2          80.2±7.5           81.8±8.4           0.177
   Female (%)                                               118 (50.4)        32 (48.5)          86 (51.2)          0.772
   Body Mass Index (kg.m^-2^)                               26.8±5.8          26.0±5.8           27.1±5.8           0.184
  NYHA functional status (%)                                                                                        
   I/II                                                     98 (41.9)         27 (40.9)          71 (42.8)          0.119
   III                                                      123 (52.6)        38 (57.6)          85 (51.2)          
   IV                                                       11 (4.7)          1 (1.5)            10 (6.0)           
   COPD (%)                                                 72 (30.8)         22 (33.3)          50 (29.8)          0.638
   Diabetes (%)                                             56 (23.9)         22 (33.3)          34 (20.2)          0.042
   PVD (%)                                                  67 (28.6)         37 (56.1)          30 (17.9)          \<0.001
   Chronic atrial fibrillation (%)                          81 (34.6)         24 (36.4)          57 (33.9)          0.761
  Concomitant significant coronary artery disease (%)                                                               
   None                                                     127 (54.3)        26 (39.4)          101 (60.1)         \<0.020
   One territory                                            51 (22.2)         16 (24.2)          35 (20.8)          
   Two territories                                          40 (17.1)         16 (24.2)          24 (14.3)          
   Three territories                                        11 (4.7)          5 (7.6)            6 (3.6)            
   Four territories                                         5 (2.1)           3 (4.5)            2 (1.2)            
  MI occurring within 90 days before the implantation (%)   9 (3.9)           4 (6.1)            5 (3.0)            0.275
  History of PCI (%)                                        97 (41.5)         31 (47.0)          66 (39.3)          0.304
  History of CABG (%)                                       39 (16.7)         10 (15.2)          29 (17.3)          0.846
  History of MVSx (%)                                       5 (2.1)           4 (6.1)            1 (0.6)            0.023
  History of AVSx (%)                                       21 (9.0)          7 (10.6)           14 (8.3)           0.614
  Stroke (%)                                                18 (7.7)          4 (6.1)            14 (8.3)           0.786
  Creatinine (mg.dL^-1^)                                    113.2±86.6        112.0±65.8         113.7±93.6         0.891
  eGFR (ml.min^-1^)                                         50.8±21.8         50.2±25.7          51.0±27.3          0.848
  Chronic renal failure (%)                                 184 (78.6)        51 (77.3)          133 (79.2)         0.727
  Pacemaker (%)                                             48 (20.4)         12 (18.2)          36 (21.4)          0.719
  Logistic EuroSCORE 1 (%)                                  22.6±12.3         25.0±11.8          21.6±12.5          0.065
  Logistic EuroSCORE 2 (%)                                  7.2±5.3           8.1±5.4            6.8±5.2            0.085
  STS-PROM Score (%)                                        7.6±3.7           7.8±3.4            7.5±3.8            0.519
  Echocardiographic characteristics                                                                                 
  LVEF (%)                                                  52.2±13.9         52.0±14.8          52.3±13.5          0.882
  Aortic mean gradient (mmHg)                               44.7±17.0         44.1±17.5          44.9±16.8          0.743
  Indexed aortic valve area (cm^2^.m^-2^)                   0.7±0.4           0.8±0.4            0.7±0.4            0.506
  Aortic regurgitation, *n* (%)                                                                                     
   None                                                     114 (48.7)        33 (50.0)          81 (48.2)          0.109
   Trace                                                    88 (37.6)         20 (30.3)          68 (40.5)          
   Mild                                                     20 (8.6)          9 (13.6)           11 (6.5)           
   Moderate                                                 8 (3.4)           4 (6.1)            4 (2.4)            
   Severe                                                   4 (1.7)           0 (0.0)            4 (2.4)            
  Mitral regurgitation, *n* (%)                                                                                     
   None                                                     48 (20.7)         10 (15.2)          38 (22.9)          0.260
   Trace                                                    117 (50.4)        37 (56.1)          80 (48.2)          
   Mild                                                     58 (25.0)         16 (24.2)          42 (25.3)          
   Moderate                                                 8 (3.5)           3 (4.5)            5 (3.0)            
   Severe                                                   1 (0.4)           0 (0.0)            1 (0.6)            
  Systolic pulmonary artery pressure \>60 mmHg, *n* (%)     30 (12.8)         13 (19.7)          31 (18.5)          0.133

Data are expressed as mean (standard deviation) for quantitative variables and as number (percentages) for categorical variables. The *P* refers to comparison between groups. TAVI-AG: TAVI under general anesthesia; TAVI-S: TAVI under conscious sedation; NYHA: New York Heart Association functional status; COPD: chronic obstructive pulmonary disease; PVD: perivascular disease; LVEF: left ventricular ejection fraction; MI: myocardial infarction; PCI: percutaneous coronary intervention; CABG: coronary artery bypass graft; MVSx: mitral valve surgery; AVSx: aortic valve surgery; eGFR: estimated glomerular filtration ratio; EuroSCORE: European System for Cardiac Operative Risk Evaluation; STS: Society of Thoracic Surgeons predicted risk of mortality; LVEF: left ventricular ejection fraction

###### 

Procedural findings

  Procedural data                                           Total (*n*=234)   TAVI-GA (*n*=66)   TAVI-S (*n*=168)   *P*       *P* adjusted\*   95% confidence interval
  --------------------------------------------------------- ----------------- ------------------ ------------------ --------- ---------------- -------------------------
  Approach, *n* (%)                                                                                                                            
   Transfemoral                                             184 (78.6)        18 (27.3)          166 (98.8)         \<0.001                    
   Transcarotid                                             23 (9.8)          23 (34.9)          0 (0.0)            \<0.001                    
   Subclavian                                               6 (2.6)           6 (9.1)            0 (0.0)            \<0.001                    
   Transaortic                                              16 (6.8)          14 (21.2)          2 (1.2)            \<0.001                    
   Transapical                                              5 (2.1)           5 (7.6)            0 (0.0)            0.002                      
  Number of patients who received a pre-dilation, *n* (%)   205 (87.6)        55 (83.3)          150 (89.3)         0.269                      
  Number of patients who received a post-dilation           34 (14.5)         6 (9.1)            28 (16.7)          0.155                      
  Success of the procedure\*\*, *n* (%)                     219 (93.6)        61 (92.4)          158 (95.2)         0.767                      
  Two valves implanted, *n* (%)                             9 (3.8)           2 (3.0)            7 (4.2)            1                          
  Type of valve implanted, *n* (%)                                                                                                             
  Self-expandable                                           121 (51.7)        37 (56.1)          84 (50.0)          0.56                       
  Balloon-expandable                                        109 (46.6)        29 (43.9)          80 (47.6)                                     
  Valve malpositioning\*\*, *n* (%)                         8 (3.4)           1 (1.5)            7 (4.2)            0.447     0.475            (0.2, 20.4)^†^
  Amount of contrast-medium injected (ml)                   136.2±64.5        113.8±59.3         143.0±64.6         0.006     0.004            (-53.9, -10.3)^‡^
  Contrast-medium adjusted to BMI (ml/kg^-1^/m^-2^)         90.4±85.6         80.5±84.4          93.4±86.0          0.372     0.367            (-43.9, 16.3)^‡^
  Length of fluoroscopy (min)                               24.7±11.1         20.5±11.8          26.0±10.6          0.002     0.022            (-8.1, -0.6)^‡^

Data are expressed as mean (standard deviation) for quantitative variables and as number (percentages) for categorical variables. The P refers to comparison between groups. TAVI-AG: TAVI under general anesthesia; TAVI-S: TAVI under conscious sedation; Asterisks definition: \*the *P* value refers to comparison between groups adjusted with a propensity score as a continuous covariate; \*\*procedural assessment based on the VARC-2 classification; ^†^95% Wald confidence limits; ^‡^95% Confidence limits of the difference

When adjusted with a propensity score the intraoperative variables found to be significantly different the results were analogous \[[Table 3](#T3){ref-type="table"}\]. The number of valve malpositioning implantations was higher in the TAVI-S group, but no significant difference was found between the two groups. All the ectopic valves implanted were self-expandable (*P* = 0.008). The procedure success rates according to the VARC 2 criteria were similar and superior to 90% in both groups.

Clinical outcomes {#sec2-5}
-----------------

In a center of reference, the incidence of moderate-to-severe PVL after the implantation is rare. At 30 days after the implantation, no moderate-to-severe PVL was detected \[[Table 4](#T4){ref-type="table"}\]. No differences regarding the incidence of moderate-to-severe PVL were observed after the procedure and at 5 days after the implantation between TAVI-GA and TAVI-S \[[Table 4](#T4){ref-type="table"}\]. The baseline covariates found to be significantly different between the two groups that were inserted in the statistical model were diabetes, concomitant significant coronary artery disease, and PVD. When adjusted with a propensity score, the incidence of moderate-to-severe PVL at 5 days was not different either (*P* = 0.528; 95% Wald confidence limits \[0.06--4.06\]). The others echocardiographic outcome data of interest are presented in [Table 4](#T4){ref-type="table"}. Five patients (2.1%) died during the procedure. Two of them were in TAVI-GA group while three of them were from TAVI-S group (*P* = 0.623). Ten patients died during the hospital stay after the implantation: 6 in the TAVR-GA group (3 because of cardiogenic shocks leading to multiple organ failures, 2 because of cardiorespiratory arrests, and 1 because of a respiratory failure). In contrast, four patients died in the TAVR-S group (two patients died because of a septic shock, one patient because of a cardiorespiratory arrest, and one patient died after a stroke). Hence, the hospital mortality rate was higher in the TAVI-GA group compared to the TAVR-S group (12.5% vs. 4.2%, *P* = 0.036). Such statistical difference did not persist neither at 30 days after the procedure (12.5% vs. 6.7%, *P* = 0.183) nor at 1 year (26.6% vs. 19.4%, *P* = 0.372). The type and rate of procedure-related complications are presented in [Table 5](#T5){ref-type="table"}. Only postimplantation life-threatening bleedings occurred significantly more often in the TAVI-GA group (*P* = 0.021). The mean length of hospital stay was 13.4 ± 7.7 days with no significant different between the two groups (*P* = 0.385).

###### 

Echocardiographic outcome data

  Transthoracic echocardiographic assessment                Total         TAVI-GA      TAVI-S        *P*
  --------------------------------------------------------- ------------- ------------ ------------- -------
  At the end of the procedure (*n*=229)                     *n*=229       *n*=64       *n*=165       
   PVL, *n* (%)                                                                                      
    None to mild                                            222 (97.0)    62 (96.9     160 (97.0)    1.000
    Moderate to severe                                      7 (3.0)       2 (3.1)      5 (3.0)       
  At 5-day (*n*=221)                                        *n*=221       *n*=60       *n*=161       
  PVL, *n* (%)                                                                                       
   None to mild                                             216 (97.7)    58 (96.7)    158 (98.1)    0.615
   Moderate to severe                                       5 (2.3)       2 (3.3)      3 (1.9)       
  Aortic mean gradient (mmHg)                               8.7±5.0       8.7±4.0      8.7±5.3       0.936
  Indexed aortic valve area (cm^2^.m^-2^)                   1.7±0.6       1.8±0.7      1.7±0.5       0.245
  LVEF (%)                                                  53.9±12.9     53.0±12.9    54.3±12.9     0.515
  Mitral regurgitation, *n* (%)                                                                      
   None                                                     59 (26.7)     15 (25.0)    44 (27.3)     0.579
   Mild                                                     109 (49.3)    31 (51.7)    78 (48.5)     
   Moderate                                                 41 (18.6)     12 (20.0)    29 (18.0)     
   Severe                                                   12 (5.4)      2 (3.3)      10 (6.2)      
  Systolic pulmonary hypertension non measurable (%)        17 (7.7)      6 (10.1)     11 (6.8)      0.409
  Systolic pulmonary hypertension (%)                       58 (28.4)     15 (27.8)    43 (28.7)     0.978
  None (\<31 mmHg)                                          135 (66.2)    36 (66.7)    99 (66.0)     
  Moderate (31-60 mmHg)                                     11 (5.4)      3 (5.6)      8 (5.3)       
  Severe (\> 60 mmHg)                                                                                
  At 30-day (*n*=193)                                       *n*=193       *n*=49       *n*=144       
  PVL, *n* (%)                                                                                       
   None to mild                                             193 (100.0)   49 (100.0)   144 (100.0)   1.000
   Moderate to severe                                       0 (0.0)       0 (0.0)      0 (0.0)       
  Aortic mean gradient (mmHg)                               7.6±4.4       8.1±5.1      7.5±4.1       
  Indexed aortic valve area (cm^2^.m^-2^)                   1.8±0.5       1.8±0.6      1.8±0.5       0.370
  LVEF (%)                                                  55.4±11.8     54.1±12.5    55.8±11.6     0.816
  Mitral regurgitation, *n* (%)                                                                      0.391
   None                                                     35 (18.2)     9 (18.4)     26 (18.2)     
   Mild                                                     115 (59.9)    32 (65.3)    83 (58.0)     
   Moderate                                                 35 (18.2)     7 (14.3)     28 (19.6)     0.327
   Severe                                                   7 (3.7)       1 (2.0)      6 (4.2)       
  Systolic pulmonary hypertension non measurable, *n* (%)   14 (7.3)      5 (10.2)     9 (6.3)       0.351
  Systolic pulmonary hypertension, *n* (%)                                                           
   None (\<31 mmHg)                                         61 (34.1)     16 (36.3)    45 (33.3)     0.565
   Mild (31-60 mmHg)                                        108 (60.3)    25 (56.8)    83 (61.5)     
   Severe (\> 60 mmHg)                                      10 (5.6)      3 (6.8)      7 (5.2)       

Data are expressed as mean (standard deviation) for quantitative variables and as number (percentages) for categorical variables. The *P* refers to comparison between groups. TAVI-AG: TAVI under general anesthesia; TAVI-S: TAVI under conscious sedation; PVL: Paravalvular leak; LVEF: left ventricular ejection fraction

###### 

Procedure related complications and all-cause mortality rate

  Procedure related complications                Total (*n*=229)   TAVI-GA (*n*=64)   TAVI-S (*n*=165)   *P*
  ---------------------------------------------- ----------------- ------------------ ------------------ -------
  Conversion to open surgery, *n* (%)            4 (1.7)           3 (4.7)            1 (0.6)            0.067
  Unplanned use of CPB, *n* (%)                  1 (0.4)           1 (1.6)            0 (0)              0.279
  Coronary obstruction, *n* (%)                  0 (0)             0 (0)              0 (0)              1.000
  New permanent pacemaker, *n* (%)               37 (16.1)         13 (20.3)          24 (14.5)          0.319
  Tamponade, *n* (%)                             5 (2.2)           3 (4.7)            2 (1.2)            0.135
  Major stroke, *n* (%)                          6 (2.6)           1 (1.6)            5 (3.3)            1.000
  Myocardial infarction, *n* (%)                 2 (0.9)           2 (3.1)            0 (0)              0.077
  Major vascular access-site bleeding, *n* (%)   21 (9.2)          3 (4.7)            18 (10.9)          0.202
  Life-threatening bleedings, *n* (%)            3 (1.3)           3 (4.7)            0 (0)              0.021
  Post-implantation infection, *n* (%)           22 (9.6)          6 (9.4)            16 (9.7)           1.000
  Acute kidney injury stage 3, *n* (%)           9 (3.9)           3 (4.7)            6 (3.6)            0.712
  Renal replacement therapy, *n* (%)             3 (1.3)           1 (1.6)            2 (1.2)            1.000

Data are expressed as number (percentages). The *P* refers to comparison between groups. TAVI-AG: TAVI under general anesthesia; TAVI-S: TAVI under conscious sedation; PVL: Paravalvular leak; LVEF: left ventricular ejection fraction; CPB: cardiopulmonary bypass

Discussion {#sec1-4}
==========

The main findings of this retrospective observational investigation demonstrated that, in an experienced center, the incidence of moderate-to-severe PVL right after the implantation and at 30 days is exceptional. In addition, our findings showed that the implantation under conscious sedation without TEE does not increase the incidence of PVL associated with long-term mortality compared to GA with TEE guidance for the correct valve deployment and to detect PVL requiring postimplantation dilation. The type of anesthesia for patients scheduled to undergo a TAVI might be of concern to anesthesiologists performing conscious sedation without TEE guidance since this anesthesia technique has been associated with an increased incidence of PVL according to the last French TAVI registry including 2326 patients\[[@ref8]\] and to a recent literature review including 5919 patients.\[[@ref18]\] The legitimacy of this concern is justified because lowering the incidence of PVL is crucial. The latter is associated with increased short- and long-term mortality post-TAVI.\[[@ref11]\] Initially, a reanalysis of the PARTNER trial data has shown that mild-to-severe PVL could increase short- and long-term mortality.\[[@ref10]\] However, the PARTNER trial did not use the VARC-2 criteria to assess PVL. The rate of PVL and its impact on mortality change significantly from one study to another.\[[@ref11]\] This is probably secondary to a lack of harmonization to grade PVL after TAVI\[[@ref11]\] although clear criteria have been proposed in that respect.\[[@ref12]\] Jerez-Valero *et al*.\[[@ref14]\] were the first to conduct a trial to determine the effect of PVL on outcomes using the VARC-2 criteria. They enrolled 1735 patients and showed that long-term mortality was significantly more frequent in patients with moderate-to-severe PVL. Based on our results, anesthesiologists performing TAVI under conscious sedation without TEE guidance in an experienced center should not be alarmed since this anesthesia technique does not lead to higher rate of moderate-to-severe PVL neither immediately after the procedure nor 30 days after the procedure. Our investigation also shows a decrease in the rate of moderate-to-severe PVL over time. This trend is well described in the literature and seems to be endorsed by the remodeling of the aortic root and caused by to the death of the patients with the most severe PVL.\[[@ref11]\] Hospital mortality rate was greater in the TAVI-GA group. Patients of this group presented more comorbidities (diabetes, peripheral vascular disease, mitral valve repair, and coronary artery disease) compared to TAVI-S group. This difference could explain the higher hospital mortality rate in the TAVI-GA group. In this group, most of the deaths had a cardiovascular etiology, whereas, in the TAVI-S group, hospital deaths had mainly an extracardiac origin (stroke and sepsis). In contrast, the mortality rate at 30 days and at 1 year were similar between the two groups. These results are in line with a recent literature review aiming to compare the safety between locoregional anesthesia with sedation and GA for TAVI procedure.\[[@ref19]\] The differences between the two groups regarding medical history might explain the significantly higher rate of life-threatening bleedings in the TAVI-GA group along with the technically more difficult procedural approach (less transfemoral approach but more transcarotid, subclavian, transaortic, and transapical approach). Interestingly, the TAVI-GA group had a significantly lower length of fluoroscopy and volume of contrast-medium injected. These differences were significant even after propensity-matched comparison. Such differences could be explained by the TEE guidance during the valve deployment in the TAVI-GA group. Lowering the volume of contrast-medium injected could be of particular interest to reduce the incidence of acute kidney injury, especially in patients with chronic kidney disease. However, contrast-induced nephropathy after TAVI is controversial and it is still not known whether this nephropathy is associative or causative.\[[@ref20]\] Our results did not reveal disparities in the incidence of acute kidney injury Stage 3 and requirement for renal replacement therapy between the two groups. Thus, considering that the implantation under sedation is associated with a faster procedure time, a shorter length of critical care unit stay, and a lower requirement of vasoconstrictor drugs,\[[@ref19]\] it could be claimed that the procedure under sedation is preferable compared to GA with TEE guidance. On the other hand, Maas *et al*.\[[@ref18]\] literature review reports that locoregional anesthesia with or without sedation is associated with an increased risk of new permanent pacemaker implantation with a risk ratio of 1.23. Dissimilarly, we did not found a significant difference in that respect. Such difference could be explained by the fact that their review included trials with centers starting to perform TAVI under sedation, which were not used to patients not being completely immobile. These conditions could have augmented the rate of inadvertent device implantation too low in the outflow tract, which could compress the conduction tissue causing atrioventricular blocks.\[[@ref21]\] Another important discrepancy of our investigation compared to Maas *et al*. meta-analysis is that we did not found a difference in the length of stay between the two study groups.\[[@ref18]\] It could be advocated that, during the transition period from GA to sedation, no practice changes occurred in discharge planning in our institution. This circumstance might have affected the time of discharge from hospital although the eligibility to be discharge may have been reached earlier in the sedation group.

There are several limitations to the present study. First, the power of the sample size was not calculated to make a comparison between TAVI-GA and TAVI-S. However, the results provide clinical hints of important value for the anesthesiologist. Second, the trial was not randomized leading to an imbalance between groups in terms of patients' medical history creating a potential selection bias. However, the differences in comorbidities could not influence the incidence of PVL, and a propensity-matched comparison was performed for the intraoperative parameters found to be significantly different. Another limitation of our study was the missing echocardiographic data in 10.2% of the patients alive at 30-day follow-up. Finally, the effect over time of PVL on left ventricular ejection function could have been misjudged since no TTE data were collected after the 30-day follow-up.

Conclusion {#sec1-5}
==========

Our study demonstrates that, in a center of reference that masters the TAVI procedure, the rate of PVL is very low compared to the overall incidence reported in the literature. GA with TEE guidance is not associated with a lower rate of moderate-to-severe PVL compared to local anesthesia plus sedation alone. An experienced center that is proficient in hemodynamic and fluoroscopic assessment does not need a GA with TEE guidance for the correct valve deployment and to deem the necessity for postimplantation dilation. Thus, when these conditions are met anesthesiologists could perform a TAVI procedure under local anesthesia plus sedation without increasing the incidence of PVL known to be associated with greater short- and long-term mortality.
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